Welcome to our dedicated page for ReShape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on ReShape Lifesciences stock.
Reshape Lifesciences, Inc. is a medical device company focused on the development of non-surgical weight loss devices for obese or overweight patients. The company offers a range of innovative products, including LAP-BAND, ReShapeCare, Obalon Balloon System, and Diabetes Bloc-Stim Neuromodulation. Reshape Lifesciences aims to provide less invasive solutions for weight loss treatment, addressing the growing demand for safe and effective options in the market.
Rhea-AI Summary
ReShape Lifesciences® announces pricing of public offering of 9.1M units at $0.33 each, expecting gross proceeds of $3.0M
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.18%
Tags
-
Rhea-AI Summary
ReShape Lifesciences to present company overview at LD Micro's Annual Main Event, highlighting Lap-Band program and ReShapeCare virtual weight-management program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
-
Rhea-AI Summary
ReShape Lifesciences signs exclusive license agreement with Biorad Medysis to distribute Obalon Gastric Balloon System in Indian Subcontinent
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.35%
Tags
Rhea-AI Summary
ReShape Lifesciences strengthens patent portfolio for Obalon Balloon System, with one patent granted and two notices of allowance received
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.64%
Tags
-
Rhea-AI Summary
ReShape Lifesciences® receives $331,541 SBIR grant for development of DBSN™ device to treat Type 2 diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
ReShape Lifesciences Inc. reports financial results for Q2 2023, with a 53% reduction in operating expenses compared to last year. The company made operational improvements and invested in growth drivers. They signed a preferred partner agreement with Hive Medical for lead optimization software. They also submitted a PMA supplement application to the FDA for their next generation Lap-Band® 2.0. Revenue contracted in Q2 2023 compared to the same period last year, but the company expects growth in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
News
Rhea-AI Summary
ReShape Lifesciences submits PMA supplement application for enhanced Lap-Band 2.0 with band reservoir technology to FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.71%
Tags
FAQ
What is the current stock price of ReShape Lifesciences (RSLS)?
The current stock price of ReShape Lifesciences (RSLS) is $4.5 as of January 10, 2025.
What is the market cap of ReShape Lifesciences (RSLS)?
The market cap of ReShape Lifesciences (RSLS) is approximately 3.3M.
What is Reshape Lifesciences, Inc. focused on?
Reshape Lifesciences, Inc. is a medical device company focused on developing non-surgical weight loss devices for obese or overweight patients.
What are some of the products offered by Reshape Lifesciences?
Reshape Lifesciences offers a range of products including LAP-BAND, ReShapeCare, Obalon Balloon System, and Diabetes Bloc-Stim Neuromodulation.
What is the goal of Reshape Lifesciences?
Reshape Lifesciences aims to provide less invasive solutions for weight loss treatment, addressing the demand for safe and effective options in the market.
How does Reshape Lifesciences contribute to the medical field?
Reshape Lifesciences contributes to the medical field by offering innovative and advanced technologies to treat obesity and metabolic diseases.
ReShape Lifesciences, Inc.
Nasdaq:RSLS
RSLS Rankings
RSLS Stock Data
3.28M
649.97k
5.58%
1.83%
4.94%
Medical Devices
Pharmaceutical Preparations
United States of America
SAN CLEMENTE